Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.59
(-0.45%)
USD 0.59
(-0.45%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.86 Million USD | 115.5% |
| 2022 | 11.1 Million USD | -55.18% |
| 2021 | 24.76 Million USD | 1.65% |
| 2020 | 24.36 Million USD | 28.16% |
| 2019 | 19.01 Million USD | 28.75% |
| 2018 | 14.76 Million USD | -11.32% |
| 2017 | 16.65 Million USD | 101.67% |
| 2016 | 8.25 Million USD | -18.29% |
| 2015 | 10.1 Million USD | -3.43% |
| 2014 | 10.46 Million USD | 181.89% |
| 2013 | 3.71 Million USD | 3098.31% |
| 2012 | 116.07 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.66 Million USD | 0.27% |
| 2024 Q2 | 5.59 Million USD | 3.13% |
| 2023 Q1 | 6.68 Million USD | 2.13% |
| 2023 Q2 | 6.15 Million USD | -7.83% |
| 2023 Q4 | 5.64 Million USD | -7.94% |
| 2023 Q3 | 6.13 Million USD | -0.41% |
| 2023 FY | 23.92 Million USD | 115.5% |
| 2022 Q2 | 6.98 Million USD | -9.51% |
| 2022 Q1 | 7.72 Million USD | 15.02% |
| 2022 FY | 11.1 Million USD | -55.18% |
| 2022 Q4 | 6.54 Million USD | 0.27% |
| 2022 Q3 | 6.52 Million USD | -6.62% |
| 2021 Q3 | 6.87 Million USD | 43.6% |
| 2021 Q4 | 6.71 Million USD | -2.38% |
| 2021 FY | 24.76 Million USD | 1.65% |
| 2021 Q2 | 4.78 Million USD | -25.0% |
| 2021 Q1 | 6.38 Million USD | -2.52% |
| 2020 FY | 24.36 Million USD | 28.16% |
| 2020 Q3 | 5.7 Million USD | -1.15% |
| 2020 Q2 | 5.76 Million USD | -9.15% |
| 2020 Q1 | 6.34 Million USD | 10.65% |
| 2020 Q4 | 6.55 Million USD | 14.93% |
| 2019 Q3 | 4.56 Million USD | -1.07% |
| 2019 Q1 | 4.1 Million USD | -1.52% |
| 2019 FY | 19.01 Million USD | 28.75% |
| 2019 Q4 | 5.73 Million USD | 25.75% |
| 2019 Q2 | 4.61 Million USD | 12.37% |
| 2018 Q4 | 4.16 Million USD | 41.04% |
| 2018 FY | 14.76 Million USD | -11.32% |
| 2018 Q3 | 2.95 Million USD | -15.47% |
| 2018 Q1 | 4.15 Million USD | -11.22% |
| 2018 Q2 | 3.49 Million USD | -15.8% |
| 2017 Q4 | 4.67 Million USD | 35.4% |
| 2017 FY | 16.65 Million USD | 101.67% |
| 2017 Q3 | 3.45 Million USD | -14.13% |
| 2017 Q2 | 4.02 Million USD | -10.68% |
| 2017 Q1 | 4.5 Million USD | 75.57% |
| 2016 Q2 | 1.62 Million USD | -27.59% |
| 2016 Q4 | 2.56 Million USD | 39.74% |
| 2016 Q3 | 1.83 Million USD | 13.26% |
| 2016 Q1 | 2.23 Million USD | -19.58% |
| 2016 FY | 8.25 Million USD | -18.29% |
| 2015 FY | 10.1 Million USD | -3.43% |
| 2015 Q4 | 2.78 Million USD | 25.41% |
| 2015 Q3 | 2.21 Million USD | -10.5% |
| 2015 Q2 | 2.47 Million USD | -5.61% |
| 2015 Q1 | 2.62 Million USD | -20.66% |
| 2014 Q1 | 2.12 Million USD | 18.03% |
| 2014 Q4 | 3.31 Million USD | 27.05% |
| 2014 Q2 | 2.42 Million USD | 13.69% |
| 2014 FY | 10.46 Million USD | 181.89% |
| 2014 Q3 | 2.6 Million USD | 7.64% |
| 2013 Q3 | 1.45 Million USD | 323.18% |
| 2013 Q2 | 343.37 Thousand USD | 206.22% |
| 2013 Q1 | 112.13 Thousand USD | 18.83% |
| 2013 Q4 | 1.8 Million USD | 24.14% |
| 2013 FY | 3.71 Million USD | 3098.31% |
| 2012 FY | 116.07 Thousand USD | 0.0% |
| 2012 Q4 | 94.36 Thousand USD | 935.34% |
| 2012 Q3 | 9114.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 22.49% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -168.256% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -113.426% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 52.189% |
| Azitra, Inc. | 8.3 Million USD | -199.456% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -178.161% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -262.299% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 14.245% |
| CEL-SCI Corporation | 31.47 Million USD | 21.013% |
| iBio, Inc. | 16.85 Million USD | -47.47% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 24.677% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -23.187% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -78.458% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -92.759% |
| NanoViricides, Inc. | 8.51 Million USD | -191.941% |
| Oragenics, Inc. | 5.45 Million USD | -356.02% |
| BiomX Inc. | 26.81 Million USD | 7.28% |
| BiomX Inc. | 26.81 Million USD | 7.28% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 22.432% |
| Palatin Technologies, Inc. | 34.67 Million USD | 28.29% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 37.557% |